The FDA has approved Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), an ultra-rare and life-threatening genetic disorder. Oxlumo (lumasiran ...

Since then, Alnylam has claimed approval for two more RNAis, Givlaari (givosiran) for acute hepatic porphyria (AHP) and Oxlumo (lumasiran) for primary hyperoxaluria type 1 (PH1). RNAi uses small ...

After hours: December 9 at 5:40:49 PM EST Loading Chart for ALNY ...

Today, the Governments of Canada and Alberta signed the National Strategy for Drugs for Rare Disease (DRD) agreement to invest a total amount of over ...

In medicine, there are four levels of care: primary, secondary, tertiary, and quaternary. The levels of care refer to the complexity of the medical cases that healthcare providers treat and the skills ...

The Governments of Canada and Alberta have announced a bilateral agreement investing over $162 million in an effort to ...

Alberta can administer the federal dental plan if it wishes, and a Pharmacare deal is near, said federal Health Minister Mark ...

*Pooled data analysis from 22 studies. † Lupus in minorities: nature versus nurture [Unpublished Observ., May 2008]. Lupus occurs only in young women Lupus may occur at any age and in both ...

Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA61 27 May 2003 27 May 2003 Guidance on the use of drugs for early thrombolysis in the treatment of acute ...

The drugs include Poteligeo for treating Sezary syndrome, Oxlumo for hyperoxaluria type 1 and ... affects about 1 in 10 million people annually, primary hyperoxalurias type 1 affects around ...